0 6 Growth growth NN 7 17 regulation regulation NN 18 21 and and CC 22 30 cellular cellular JJ 31 38 changes change NNS 39 45 during during IN 46 61 differentiation differentiation NN 62 64 of of IN 65 70 human human JJ 71 80 prostatic prostatic JJ 81 87 cancer cancer NN 88 93 LNCaP lncap NN 94 99 cells cell NNS 100 102 as as IN 103 110 induced induce VBN 111 113 by by IN 114 115 T t NN 116 138 lymphocyte-conditioned lymphocyte-conditioned JJ 139 145 medium medium NN 145 146 . . . 148 153 Human human JJ 154 163 prostatic prostatic JJ 164 174 epithelial epithelial JJ 175 180 cells cell NNS 181 185 from from IN 186 188 an an DT 189 207 androgen-dependent androgen-dependent JJ 208 213 LNCaP LNCaP NNP 214 218 cell cell NN 219 223 line line NN 224 228 were be VBD 229 237 examined examine VBN 238 240 in in IN 241 249 response response NN 250 252 to to TO 253 264 conditioned condition VBN 265 271 medium medium NN 272 273 ( ( ( 273 275 CM CM NNP 275 276 ) ) ) 277 284 derived derive VBN 285 289 from from IN 290 308 phytohemagglutinin phytohemagglutinin NN 309 310 ( ( ( 310 325 PHA)-stimulated pha)-stimulated JJ 326 337 lymphocytes lymphocyte NNS 337 338 . . . 339 347 Addition addition NN 348 350 of of IN 351 353 CM CM NNP 354 360 caused cause VBD 361 362 a a DT 363 370 greater great JJR 371 375 than than IN 376 378 70 70 CD 378 379 % % NN 380 389 reduction reduction NN 390 392 of of IN 393 397 cell cell NN 398 411 proliferation proliferation NN 412 414 by by IN 415 419 cell cell NN 420 428 counting counting NN 429 432 and and CC 433 437 cell cell NN 438 443 cycle cycle NN 443 444 . . . 445 450 These these DT 451 456 cells cell NNS 457 463 showed show VBD 464 466 G1 g1 NN 467 472 phase phase NN 473 479 arrest arrest NN 480 483 and and CC 484 487 the the DT 488 501 clonogenicity clonogenicity NN 502 505 was be VBD 506 513 reduced reduce VBN 513 514 . . . 515 518 The the DT 519 536 growth-modulating growth-modulating JJ 537 543 effect effect NN 544 547 was be VBD 548 562 dose-dependent dose-dependent JJ 563 566 and and CC 567 570 not not RB 571 574 due due JJ 575 577 to to TO 578 582 cell cell NN 583 588 lysis lysis NN 589 591 or or CC 592 601 apoptosis apoptosis NN 601 602 . . . 603 606 The the DT 607 614 binding binding NN 615 617 of of IN 618 626 androgen androgen NN 627 629 to to TO 630 638 androgen androgen NN 639 647 receptor receptor NN 648 650 on on IN 651 656 these these DT 657 662 cells cell NNS 663 669 showed show VBD 670 683 approximately approximately RB 684 686 50 50 CD 686 687 % % NN 688 697 reduction reduction NN 697 698 , , , 699 710 underlining underline VBG 711 712 a a DT 713 726 proliferation proliferation NN 727 736 reduction reduction NN 737 746 mechanism mechanism NN 746 747 . . . 748 751 The the DT 752 769 prostate-specific prostate-specific JJ 770 777 antigen antigen NN 778 779 ( ( ( 779 782 PSA PSA NNP 782 783 ) ) ) 784 787 was be VBD 788 801 downregulated downregulate VBN 802 804 to to TO 805 818 approximately approximately RB 819 821 75 75 CD 821 822 % % NN 823 829 during during IN 830 833 the the DT 834 841 process process NN 841 842 . . . 843 847 Cell cell NN 848 858 morphology morphology NN 859 865 showed show VBD 866 875 dendritic dendritic JJ 876 885 processes process NNS 886 895 extending extend VBG 896 900 from from IN 901 910 cytoplasm cytoplasm NN 911 914 and and CC 915 920 other other JJ 921 935 neuroendocrine neuroendocrine JJ 936 940 cell cell NN 941 956 characteristics characteristic NNS 956 957 . . . 958 961 The the DT 962 972 expression expression NN 973 975 of of IN 976 983 several several JJ 984 996 cytoskeleton cytoskeleton NN 997 1000 and and CC 1001 1014 intracellular intracellular JJ 1015 1023 proteins protein NNS 1024 1033 increased increase VBD 1034 1036 as as IN 1037 1047 determined determine VBN 1048 1050 by by IN 1051 1065 immunostaining immunostaining NN 1066 1068 on on IN 1069 1075 slides slide NNS 1076 1079 and and CC 1080 1082 by by IN 1083 1088 ELISA ELISA NNP 1089 1099 procedures procedure NNS 1099 1100 . . . 1101 1106 These these DT 1107 1115 included include VBD 1116 1124 vimentin vimentin NN 1124 1125 , , , 1126 1137 correlating correlate VBG 1138 1140 to to TO 1141 1145 cell cell NN 1146 1151 shape shape NN 1152 1159 changes change NNS 1159 1160 , , , 1161 1173 cytokeratins cytokeratin NNS 1174 1175 8 8 CD 1176 1179 and and CC 1180 1182 18 18 CD 1182 1183 , , , 1184 1194 associated associate VBN 1195 1199 with with IN 1200 1214 differentiated differentiate VBN 1215 1219 cell cell NN 1220 1225 types type NNS 1226 1228 of of IN 1229 1237 prostate prostate NN 1238 1247 epithelia epithelia NN 1247 1248 , , , 1249 1252 and and CC 1253 1268 neuron-specific neuron-specific JJ 1269 1276 enolase enolase NN 1277 1280 and and CC 1281 1290 serotonin serotonin NN 1290 1291 , , , 1292 1302 associated associate VBN 1303 1307 with with IN 1308 1322 neuroendocrine neuroendocrine JJ 1323 1328 cells cell NNS 1328 1329 . . . 1330 1334 From from IN 1335 1340 these these DT 1341 1349 cellular cellular JJ 1350 1357 changes change NNS 1357 1358 , , , 1359 1361 we we PRP 1362 1365 can can MD 1366 1371 infer infer VB 1372 1376 that that IN 1377 1380 the the DT 1381 1385 cell cell NN 1386 1392 growth growth NN 1393 1396 was be VBD 1397 1406 modulated modulate VBN 1407 1412 along along IN 1413 1417 with with IN 1418 1427 induction induction NN 1428 1430 of of IN 1431 1439 terminal terminal JJ 1440 1455 differentiation differentiation NN 1455 1456 . . . 1457 1466 Activated activate VBN 1467 1468 T t NN 1469 1474 cells cell NNS 1475 1479 were be VBD 1480 1492 demonstrated demonstrate VBN 1493 1495 to to TO 1496 1498 be be VB 1499 1508 important important JJ 1509 1511 in in IN 1512 1521 providing provide VBG 1522 1525 the the DT 1526 1536 modulating modulating NN 1537 1545 activity activity NN 1545 1546 . . . 1547 1551 This this DT 1552 1558 growth growth NN 1559 1568 modulator modulator NN 1569 1572 was be VBD 1573 1585 semipurified semipurifie VBN 1586 1589 and and CC 1590 1593 had have VBD 1594 1596 an an DT 1597 1606 estimated estimate VBN 1607 1616 molecular molecular JJ 1617 1623 weight weight NN 1624 1630 13,000 13,000 CD 1631 1633 to to TO 1634 1640 24,000 24,000 CD 1641 1643 Da Da NNP 1643 1644 . . . 1645 1648 The the DT 1649 1657 activity activity NN 1658 1661 was be VBD 1662 1672 determined determine VBN 1673 1675 to to TO 1676 1678 be be VB 1679 1687 distinct distinct JJ 1688 1692 from from IN 1693 1696 TGF TGF NNP 1696 1697 , , , 1698 1701 TNF TNF NNP 1701 1702 , , , 1703 1706 and and CC 1707 1711 some some DT 1712 1720 commonly commonly RB 1721 1726 known know VBN 1727 1738 lymphokines lymphokine NNS 1738 1739 . . . 1740 1743 The the DT 1744 1755 interaction interaction NN 1756 1763 between between IN 1764 1772 lymphoid lymphoid JJ 1773 1776 and and CC 1777 1786 prostatic prostatic JJ 1787 1792 cells cell NNS 1793 1795 in in IN 1796 1802 growth growth NN 1803 1806 and and CC 1807 1818 development development NN 1819 1821 is be VBZ 1822 1831 described describe VBN 1831 1832 . . .